# OnCo record colorectal (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/colorectal/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "colorectal" ;
  schema:name "Colorectal cancer"@en ;
  schema:alternateName "COAD"@en, "COADREAD"@en, "TCGA-COAD"@en, "TCGA-COADREAD"@en, "colorectal adenocarcinoma (TCGA COAD and READ cohorts)"@en, "Rectal Cancer"@en, "Bowel cancer"@en, "Colorectal adenocarcinoma"@en, "Cancer of the colon and rectum"@en, "Large bowel cancer"@en, "CRC"@en ;
  schema:description "The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."@en ;
  schema:url <https://onco.cc/cancers/colorectal/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Colorectal_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q188874> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1461>, <https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1429>, <https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-gastrointestinal-cancers/>, <https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq>, <https://www.nhs.uk/conditions/bowel-cancer/>, <https://www.nhs.uk/conditions/bowel-cancer/symptoms/>, <https://www.nhs.uk/conditions/bowel-cancer/tests-and-next-steps/>, <https://www.nhs.uk/conditions/bowel-cancer/treatment/>, <https://www.nhs.uk/tests-and-treatments/colostomy/recovery-and-lifestyle-changes-after-a-colostomy/>, <https://www.nhs.uk/tests-and-treatments/colostomy/complications-of-a-colostomy/>, <https://www.nhs.uk/tests-and-treatments/genetic-and-genomic-testing/>, <https://www.nhs.uk/tests-and-treatments/clinical-trials/>, <https://www.nice.org.uk/guidance/ng151/chapter/Recommendations>, <https://www.bowelcanceruk.org.uk/about-bowel-cancer/treatment/surgery/stomas/>, <https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/change-in-bowel-habit-after-treatment/>, <https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/long-term-and-late-side-effects/>, <https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/body-image-and-sex/>, <https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/fertility/>, <https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/work,-money-and-travel/>, <https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/sleep-and-fatigue/>, <https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/diet-after-treatment/>, <https://www.bowelcanceruk.org.uk/about-bowel-cancer/diagnosis/questions-to-ask/>, <https://www.bowelcanceruk.org.uk/about-bowel-cancer/treatment/prehabilitation/>, <https://www.bowelcanceruk.org.uk/about-bowel-cancer/treatment/clinical-trials/>, <https://www.bowelcanceruk.org.uk/about-bowel-cancer/treatment/getting-a-second-opinion/>, <https://www.bowelcanceruk.org.uk/about-bowel-cancer/end-of-life-care/>, <https://www.bowelcanceruk.org.uk/about-bowel-cancer/advanced-bowel-cancer/treating-advanced-bowel-cancer/>, <https://www.bowelcanceruk.org.uk/campaigning/never-too-young/lynch-syndrome/>, <https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/emotional-wellbeing/supporting-someone-with-bowel-cancer/>, <https://www.macmillan.org.uk/cancer-information-and-support/bowel-cancer>, <https://www.macmillan.org.uk/cancer-information-and-support/bowel-cancer/managing-bowel-changes-after-treatment>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/surgery-to-remove-colon-cancer>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/surgery-to-remove-rectal-cancer>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/chemotherapy-for-bowel-cancer>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/chemoradiation-for-rectal-cancer>, <https://www.macmillan.org.uk/cancer-information-and-support/bowel-cancer/multidisciplinary-team-for-bowel-cancer>, <https://www.macmillan.org.uk/cancer-information-and-support/bowel-cancer/tests-on-the-bowel-cancer-cells>, <https://www.macmillan.org.uk/cancer-information-and-support/bowel-cancer/treatment-for-advanced-bowel-cancer>, <https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/sex-life-and-bowel-cancer>, <https://www.cancerresearchuk.org/about-cancer/bowel-cancer/living-with>, <https://www.cancerresearchuk.org/about-cancer/bowel-cancer/living-with/bowel-changes-after-treatment>, <https://www.cancerresearchuk.org/about-cancer/bowel-cancer/living-with/having-stoma>, <https://www.cancerresearchuk.org/about-cancer/bowel-cancer/living-with/eating>, <https://www.cancerresearchuk.org/about-cancer/bowel-cancer/living-with/sex-life>, <https://www.cancerresearchuk.org/about-cancer/bowel-cancer/living-with/coping>, <https://www.colostomyuk.org/information/managing-your-colostomy/>, <https://www.colostomyuk.org/information/diet/>, <https://www.colostomyuk.org/information/prescriptions/>, <https://www.maggies.org/support-and-information/>, <https://www.mariecurie.org.uk/information/getting-care/palliative-care>, <https://www.natcan.org.uk/reports/nboca-state-of-the-nation-report-2025/>, <https://www.bowelcanceruk.org.uk/>, <https://gco.iarc.who.int/media/globocan/factsheets/cancers/8-colon-fact-sheet.pdf>, <https://gco.iarc.who.int/media/globocan/factsheets/cancers/9-rectum-fact-sheet.pdf>, <https://seer.cancer.gov/statfacts/html/colorect.html>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/incidence>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/mortality>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/survival>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/risk-factors>, <https://www.cancerresearchuk.org/about-cancer/bowel-cancer/stages-types-and-grades/TNM-staging>, <https://www.cancerresearchuk.org/about-cancer/bowel-cancer/stages-types-and-grades/grades-and-types>, <https://www.cancerresearchuk.org/about-cancer/bowel-cancer/survival>, <https://www.cancerresearchuk.org/about-cancer/bowel-cancer/symptoms>, <https://www.nhs.uk/tests-and-treatments/bowel-cancer-screening/>, <https://www.gov.uk/guidance/bowel-cancer-screening-programme-overview>, <https://www.gov.uk/government/publications/bowel-cancer-screening-programme-standards/bowel-cancer-screening-programme-standards-reporting-from-1-april-2025>, <https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer>, <https://www.nice.org.uk/guidance/dg56>, <https://doi.org/10.1001/jama.2021.6238>, <https://doi.org/10.1136/gutjnl-2019-319915>, <https://doi.org/10.3322/caac.70067>, <https://doi.org/10.3322/caac.21772>, <https://doi.org/10.1136/gutjnl-2019-319511>, <https://doi.org/10.1056/nejm199305133281901>, <https://doi.org/10.1016/s0140-6736(17)30396-3>, <https://doi.org/10.1056/nejmoa2208375>, <https://doi.org/10.1038/s41416-022-01919-y>, <https://doi.org/10.1056/nejm198809013190901>, <https://doi.org/10.1016/0092-8674(90)90186-i>, <https://doi.org/10.1111/his.12055>, <https://doi.org/10.1080/17474124.2025.2509797>, <https://doi.org/10.1056/nejm199312303292701>, <https://doi.org/10.1056/nejmoa1100370>, <https://doi.org/10.1136/gutjnl-2019-319858>, <https://doi.org/10.1055/a-1185-3109>, <https://doi.org/10.1016/s0140-6736(20)30366-4>, <https://doi.org/10.1111/his.13975>, <https://doi.org/10.1002/bjs.1800691019>, <https://doi.org/10.1016/s0140-6736(86)92612-7>, <https://doi.org/10.1200/jco.2007.12.7027>, <https://doi.org/10.1136/bmj.38937.646400.55>, <https://doi.org/10.1097/sla.0000000000001193>, <https://doi.org/10.1016/s0140-6736(18)31078-x>, <https://doi.org/10.1200/jco.22.00032>, <https://doi.org/10.1200/jco.23.01208>, <https://doi.org/10.1016/s0140-6736(08)60455-9>, <https://doi.org/10.1016/s1470-2045(09)70330-4>, <https://doi.org/10.1016/s1470-2045(20)30599-4>, <https://doi.org/10.1002/bjs.7032>, <https://doi.org/10.1093/bjs/znac141>, <https://doi.org/10.1200/jco.22.00046>, <https://doi.org/10.1158/1055-9965.epi-16-0693>, <https://doi.org/10.1136/gutjnl-2015-309675>, <https://doi.org/10.1016/j.giec.2021.08.007> ;
  onco:tag "gi", "spike" ;
  onco:related <https://onco.cc/collections/colorectal-cancer-alliance/>, <https://onco.cc/biomarkers/msi-high/>, <https://onco.cc/biomarkers/dmmr-ihc/>, <https://onco.cc/biomarkers/braf-v600e/>, <https://onco.cc/biomarkers/braf-class-ii-iii/>, <https://onco.cc/biomarkers/kras-g12c/>, <https://onco.cc/biomarkers/kras-g12d/>, <https://onco.cc/biomarkers/her2-ish-amplified/>, <https://onco.cc/biomarkers/her2-ihc-3-plus/>, <https://onco.cc/biomarkers/tmb-high/>, <https://onco.cc/biomarkers/ctdna-mrd-positive/>, <https://onco.cc/biomarkers/ntrk-fusion/>, <https://onco.cc/biomarkers/ret-fusion/>, <https://onco.cc/biomarkers/pik3ca-hotspot-mutation/>, <https://onco.cc/roadmaps/colorectal-roadmap/>, <https://onco.cc/ideas/idea-crc-early-onset-cause-hunt/>, <https://onco.cc/ideas/idea-crc-screening-uptake-and-age-extension/>, <https://onco.cc/ideas/idea-crc-ctdna-de-escalation-beyond-stage-ii/>, <https://onco.cc/ideas/idea-crc-organ-preservation-randomised-in-pmmr-rectal/>, <https://onco.cc/ideas/idea-crc-mss-immunotherapy-by-biomarker-not-by-line/>, <https://onco.cc/ideas/idea-crc-peritoneal-disease-found-early-and-treated-in-networks/>, <https://onco.cc/ideas/idea-crc-exercise-as-a-funded-treatment/>, <https://onco.cc/ideas/idea-crc-uk-colonoscopy-capacity-and-fit-threshold/>, <https://onco.cc/ideas/idea-crc-uk-young-patient-referral-and-diagnostic-interval/>, <https://onco.cc/cancers/colorectal-micropapillary-carcinoma/>, <https://onco.cc/cancers/colorectal-adenoma-like-adenocarcinoma/>, <https://onco.cc/cancers/lynch-associated-colorectal-cancer/>, <https://onco.cc/cancers/fap-associated-colorectal-cancer/>, <https://onco.cc/cancers/colon-cancer/>, <https://onco.cc/cancers/rectal-cancer/>, <https://onco.cc/cancers/colorectal-mucinous-adenocarcinoma/>, <https://onco.cc/cancers/colorectal-signet-ring-cell-carcinoma/>, <https://onco.cc/cancers/colorectal-medullary-carcinoma/>, <https://onco.cc/cancers/colorectal-serrated-adenocarcinoma/>, <https://onco.cc/cancers/early-onset-colorectal/>, <https://onco.cc/cancers/anal/>, <https://onco.cc/cancers/small-bowel/>, <https://onco.cc/cancers/appendiceal/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/mced/>, <https://onco.cc/technologies/hipec/>, <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/technologies/probiotics-treatment-diarrhoea/>, <https://onco.cc/technologies/hydrazine-sulfate/>, <https://onco.cc/technologies/colorectal-screening/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/exercise-oncology/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/prehabilitation/>, <https://onco.cc/technologies/eras-perioperative-nutrition/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/cea-surveillance-colorectal/>, <https://onco.cc/technologies/msi-mmr-testing/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/financial-navigation/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/technologies/exercise-during-chemotherapy/>, <https://onco.cc/technologies/microwave-rf-ablation/>, <https://onco.cc/technologies/oncology-pharmacogenomics/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/organoids/>, <https://onco.cc/technologies/wes-wgs/>, <https://onco.cc/technologies/rna-seq/>, <https://onco.cc/technologies/tmb-testing/>, <https://onco.cc/technologies/continuous-ctdna-monitoring/>, <https://onco.cc/technologies/cytogenetics-fish/>, <https://onco.cc/terms/colonoscopy/>, <https://onco.cc/terms/endoscopy/>, <https://onco.cc/drugs/cologuard/>, <https://onco.cc/drugs/signatera/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/radiotherapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/hipec-pipac-devices/>, <https://onco.cc/technologies/endoscopic-resection/>, <https://onco.cc/technologies/companion-diagnostic/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/aspirin-cancer-prevention/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/apc/>, <https://onco.cc/targets/nras/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/smad4/>, <https://onco.cc/targets/fbxw7/>, <https://onco.cc/targets/mmr/>, <https://onco.cc/targets/pole/>, <https://onco.cc/targets/pold1/>, <https://onco.cc/targets/rnf43/>, <https://onco.cc/targets/rspo3/>, <https://onco.cc/targets/ctnnb1/>, <https://onco.cc/targets/amer1/>, <https://onco.cc/targets/sox9/>, <https://onco.cc/targets/arid1a/>, <https://onco.cc/targets/tgfbr2/>, <https://onco.cc/targets/b2m/>, <https://onco.cc/targets/tcf7l2/>, <https://onco.cc/targets/myc-gene/>, <https://onco.cc/targets/ret/>, <https://onco.cc/targets/alk/>, <https://onco.cc/targets/pten/> ;
  onco:drugs <https://onco.cc/drugs/therascreen-cdx/>, <https://onco.cc/drugs/tempus-xt-cdx/>, <https://onco.cc/drugs/caris-mi-cancer-seek/>, <https://onco.cc/drugs/oncodetect/>, <https://onco.cc/drugs/ziv-aflibercept/>, <https://onco.cc/drugs/catumaxomab/>, <https://onco.cc/drugs/tegafur-gimeracil-oteracil/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/panitumumab/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/lapatinib/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/botensilimab/>, <https://onco.cc/drugs/balstilimab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/signatera/>, <https://onco.cc/drugs/guardant-reveal/>, <https://onco.cc/drugs/foundationone-cdx/>, <https://onco.cc/drugs/guardant360-cdx/>, <https://onco.cc/drugs/trusight-oncology-comprehensive/>, <https://onco.cc/drugs/ventana-mmr-rxdx/>, <https://onco.cc/drugs/folfoxiri/>, <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/cobimetinib/>, <https://onco.cc/drugs/mitomycin/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/dostarlimab/> ;
  onco:companies <https://onco.cc/companies/ambagon-therapeutics/>, <https://onco.cc/companies/mabwell-shanghai-bioscience/>, <https://onco.cc/companies/multitude-therapeutics/>, <https://onco.cc/companies/neonc-technologies/>, <https://onco.cc/companies/oncolytics-biotech/>, <https://onco.cc/companies/shanghai-kechow-pharma/>, <https://onco.cc/companies/shenzhen-ionova-life-sciences/>, <https://onco.cc/companies/mbrace-therapeutics/>, <https://onco.cc/companies/stcube/>, <https://onco.cc/companies/tiumbio/>, <https://onco.cc/companies/vyriad/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/amgen/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/takeda/>, <https://onco.cc/companies/servier/>, <https://onco.cc/companies/gsk/>, <https://onco.cc/companies/guardant-health/>, <https://onco.cc/companies/natera/>, <https://onco.cc/companies/exact-sciences/>, <https://onco.cc/companies/eli-lilly/>, <https://onco.cc/companies/bayer/>, <https://onco.cc/companies/alliance-oncology/> ;
  onco:institutions <https://onco.cc/institutions/nki/>, <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/ncc-japan/>, <https://onco.cc/institutions/johns-hopkins/>, <https://onco.cc/institutions/bowel-cancer-uk/>, <https://onco.cc/institutions/bowel-research-uk/>, <https://onco.cc/institutions/leeds-cancer-centre/>, <https://onco.cc/institutions/birmingham-cancer-centre/>, <https://onco.cc/institutions/oxford-cancer/>, <https://onco.cc/institutions/royal-marsden/>, <https://onco.cc/institutions/beatson-glasgow/>, <https://onco.cc/institutions/nottingham-cancer-centre/>, <https://onco.cc/institutions/imperial-cancer-centre/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/wnt/>, <https://onco.cc/pathways/colorectal-cancer-signalling/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/vegf-angiogenesis/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/tgf-beta/>, <https://onco.cc/pathways/mismatch-repair-msi/>, <https://onco.cc/pathways/replication-stress/>, <https://onco.cc/pathways/chromosomal-instability/>, <https://onco.cc/pathways/epigenetic-reprogramming/>, <https://onco.cc/pathways/swi-snf-chromatin/>, <https://onco.cc/pathways/myc/>, <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/antigen-presentation-immunoediting/>, <https://onco.cc/pathways/immune-desert-exclusion/>, <https://onco.cc/pathways/caf-activation-desmoplasia/>, <https://onco.cc/pathways/tumor-microenvironment/>, <https://onco.cc/pathways/clonal-evolution/>, <https://onco.cc/pathways/field-cancerisation/>, <https://onco.cc/pathways/mutagenesis-signatures/>, <https://onco.cc/pathways/cancer-immunity-cycle/> ;
  onco:terms <https://onco.cc/terms/msi/>, <https://onco.cc/terms/sidedness/>, <https://onco.cc/terms/cms-subtypes/>, <https://onco.cc/terms/lynch-syndrome/>, <https://onco.cc/terms/fit-test/>, <https://onco.cc/terms/clinical-complete-response/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/stoma/>, <https://onco.cc/terms/colectomy/>, <https://onco.cc/terms/total-mesorectal-excision/>, <https://onco.cc/terms/total-neoadjuvant-therapy/>, <https://onco.cc/terms/organ-preservation/>, <https://onco.cc/terms/hepatectomy/>, <https://onco.cc/terms/peripheral-neuropathy/>, <https://onco.cc/terms/hand-foot-syndrome/>, <https://onco.cc/terms/rash-skin-toxicity/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/terms/mucositis/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/financial-toxicity/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/terms/curative-intent/>, <https://onco.cc/terms/mss-pmmr/>, <https://onco.cc/terms/mlh1-promoter-methylation/>, <https://onco.cc/terms/malnutrition-screening/>, <https://onco.cc/terms/nutrition-impact-symptoms/>, <https://onco.cc/terms/liver-directed-therapy/>, <https://onco.cc/terms/colonoscopy/>, <https://onco.cc/terms/pole-ultramutation/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/cfdna/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/fish/>, <https://onco.cc/terms/wild-type/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/terms/hereditary-cancer-syndromes/>, <https://onco.cc/terms/neoantigen/>, <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/immune-exclusion/>, <https://onco.cc/terms/mutational-signature/>, <https://onco.cc/terms/somatic-mutations-wxs-wgs/>, <https://onco.cc/terms/tumour-informed-assay/>, <https://onco.cc/terms/copy-number-variation-term/>, <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/gene-amplification/>, <https://onco.cc/terms/kras-mutation-subtypes/>, <https://onco.cc/terms/vus/>, <https://onco.cc/targets/mmr/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/terms/complete-response/>, <https://onco.cc/terms/colorectal-trials-open-today/>, <https://onco.cc/terms/colorectal-palliation-obstruction-pain/>, <https://onco.cc/terms/colorectal-failed-programmes/>, <https://onco.cc/terms/colorectal-uk-drug-access/>, <https://onco.cc/terms/cancer-drugs-fund/>, <https://onco.cc/terms/debulking/>, <https://onco.cc/terms/radiofrequency-ablation/>, <https://onco.cc/terms/oligometastatic/>, <https://onco.cc/terms/adenoma-carcinoma-sequence/>, <https://onco.cc/terms/serrated-pathway/>, <https://onco.cc/terms/colorectal-polyp-types/>, <https://onco.cc/terms/bowel-cancer-screening-uk/>, <https://onco.cc/terms/colonoscopy-surveillance-intervals/>, <https://onco.cc/terms/watch-and-wait-rectal-cancer/>, <https://onco.cc/terms/circumferential-resection-margin/>, <https://onco.cc/terms/obstructing-colorectal-cancer/>, <https://onco.cc/terms/liver-limited-metastatic-colorectal/>, <https://onco.cc/terms/conversion-therapy-colorectal/>, <https://onco.cc/terms/colorectal-peritoneal-metastases/>, <https://onco.cc/terms/adenoma-detection-rate/>, <https://onco.cc/terms/interval-cancer/>, <https://onco.cc/terms/screening-uptake/>, <https://onco.cc/terms/faecal-occult-blood-test/>, <https://onco.cc/terms/cytoreductive-surgery/>, <https://onco.cc/terms/peritoneal-carcinomatosis-index/>, <https://onco.cc/terms/colibactin/>, <https://onco.cc/terms/extended-ras-testing/>, <https://onco.cc/terms/anti-egfr-rechallenge/>, <https://onco.cc/terms/cimp/>, <https://onco.cc/terms/immunoscore/>, <https://onco.cc/terms/heracles-criteria/>, <https://onco.cc/terms/rspo-fusion/>, <https://onco.cc/terms/low-anterior-resection-syndrome/>, <https://onco.cc/terms/living-with-a-stoma-bowel-cancer/>, <https://onco.cc/terms/chemotherapy-side-effects-colorectal/>, <https://onco.cc/terms/urgent-help-bowel-cancer/>, <https://onco.cc/terms/lynch-syndrome-testing-uk/>, <https://onco.cc/terms/sex-fertility-after-bowel-cancer/>, <https://onco.cc/terms/work-and-money-bowel-cancer-uk/>, <https://onco.cc/terms/carers-bowel-cancer-uk/>, <https://onco.cc/terms/emergency-presentation/>, <https://onco.cc/terms/tnm-staging/>, <https://onco.cc/terms/tumour-grade/>, <https://onco.cc/terms/peritoneal-metastasis/>, <https://onco.cc/terms/stage-shift/> ;
  onco:trials <https://onco.cc/trials/nordicc/>, <https://onco.cc/trials/symbiotic-gi-03/>, <https://onco.cc/trials/nct07525206/>, <https://onco.cc/trials/nct06614192/>, <https://onco.cc/trials/nct06997497/>, <https://onco.cc/trials/nct06686576/>, <https://onco.cc/trials/nct05141721/>, <https://onco.cc/trials/nct05945901/>, <https://onco.cc/trials/nct03659448/>, <https://onco.cc/trials/proceade-crc-03/>, <https://onco.cc/trials/nct07284849/>, <https://onco.cc/trials/cao-aro-aio-94/>, <https://onco.cc/trials/rapido/>, <https://onco.cc/trials/nct06199973/>, <https://onco.cc/trials/nct04854668/>, <https://onco.cc/trials/nct07221357/>, <https://onco.cc/trials/nct07775287/>, <https://onco.cc/trials/nct07219238/>, <https://onco.cc/trials/nct07228832/>, <https://onco.cc/trials/nct07412613/>, <https://onco.cc/trials/nct05425940/>, <https://onco.cc/trials/nct06252649/>, <https://onco.cc/trials/nct04547166/>, <https://onco.cc/trials/nct07462143/>, <https://onco.cc/trials/nct07454720/>, <https://onco.cc/trials/nct07722494/>, <https://onco.cc/trials/nct06497985/>, <https://onco.cc/trials/nct07702032/>, <https://onco.cc/trials/nct07361003/>, <https://onco.cc/trials/nct04793958/>, <https://onco.cc/trials/nct07676162/>, <https://onco.cc/trials/nct05890742/>, <https://onco.cc/trials/nct05709249/>, <https://onco.cc/trials/nct06951503/>, <https://onco.cc/trials/nct06662786/>, <https://onco.cc/trials/nct07669454/>, <https://onco.cc/trials/nct06750094/>, <https://onco.cc/trials/mountaineer/>, <https://onco.cc/trials/nct07669519/>, <https://onco.cc/trials/nct05855200/>, <https://onco.cc/trials/nct05239741/>, <https://onco.cc/trials/nct06968221/>, <https://onco.cc/trials/quasar/>, <https://onco.cc/trials/scot/>, <https://onco.cc/trials/cr07/>, <https://onco.cc/trials/coin/>, <https://onco.cc/trials/foxtrot/>, <https://onco.cc/trials/mercury/>, <https://onco.cc/trials/star-trec/>, <https://onco.cc/trials/nottingham-fob/>, <https://onco.cc/trials/ukfss/>, <https://onco.cc/trials/heracles/>, <https://onco.cc/trials/crystal-fire3/>, <https://onco.cc/trials/circulate-japan/>, <https://onco.cc/trials/prodige-23/>, <https://onco.cc/trials/opra/>, <https://onco.cc/trials/mosaic/>, <https://onco.cc/trials/idea-collaboration/>, <https://onco.cc/trials/tosca/>, <https://onco.cc/trials/petacc-8/>, <https://onco.cc/trials/n0147/>, <https://onco.cc/trials/dutch-tme-trial/>, <https://onco.cc/trials/stockholm-iii/>, <https://onco.cc/trials/stellar-rectal/>, <https://onco.cc/trials/cao-aro-aio-12/>, <https://onco.cc/trials/iwwd/>, <https://onco.cc/trials/avf2107g/>, <https://onco.cc/trials/prime/>, <https://onco.cc/trials/opus/>, <https://onco.cc/trials/calgb-80405/>, <https://onco.cc/trials/tribe/>, <https://onco.cc/trials/tribe2/>, <https://onco.cc/trials/velour/>, <https://onco.cc/trials/raise/>, <https://onco.cc/trials/correct/>, <https://onco.cc/trials/concur/>, <https://onco.cc/trials/recourse/>, <https://onco.cc/trials/fresco/>, <https://onco.cc/trials/cairo3/>, <https://onco.cc/trials/cairo5/>, <https://onco.cc/trials/swog-s1406/>, <https://onco.cc/trials/destiny-crc01/>, <https://onco.cc/trials/mountaineer-03/>, <https://onco.cc/trials/imblaze370/>, <https://onco.cc/trials/eortc-40983/>, <https://onco.cc/trials/new-epoc/>, <https://onco.cc/trials/clocc/>, <https://onco.cc/trials/prodige-7/>, <https://onco.cc/trials/colopec/>, <https://onco.cc/trials/prophylochip/>, <https://onco.cc/trials/dynamic-iii/>, <https://onco.cc/trials/altair/>, <https://onco.cc/trials/chronos/>, <https://onco.cc/trials/cave/>, <https://onco.cc/trials/swedish-rectal-cancer-trial/>, <https://onco.cc/trials/minnesota-fob/>, <https://onco.cc/trials/funen-fob/>, <https://onco.cc/trials/national-polyp-study/>, <https://onco.cc/trials/netherlands-hipec/>, <https://onco.cc/trials/checkmate-142/>, <https://onco.cc/trials/co-17/>, <https://onco.cc/trials/petacc-3/>, <https://onco.cc/trials/triumph/> ;
  onco:people <https://onco.cc/people/chadwick-boseman/>, <https://onco.cc/people/angelita-habr-gama/>, <https://onco.cc/people/michael-bretthauer/>, <https://onco.cc/people/aimery-de-gramont/>, <https://onco.cc/people/david-sebag-montefiore/>, <https://onco.cc/people/matt-seymour/>, <https://onco.cc/people/dion-morton/>, <https://onco.cc/people/john-burn/>, <https://onco.cc/people/rachel-kerr/>, <https://onco.cc/people/tim-maughan/>, <https://onco.cc/people/naureen-starling/>, <https://onco.cc/people/ian-chau/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-early-detection/>, <https://onco.cc/bottlenecks/b-prevention-adoption/>, <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-dormancy-mrd/>, <https://onco.cc/bottlenecks/b-workforce/>, <https://onco.cc/bottlenecks/b-care-fragmentation/>, <https://onco.cc/bottlenecks/b-survivorship/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-capp2-aspirin-lynch-lancet-2020/>, <https://onco.cc/key-papers/paper-lynch-frameshift-vaccine-ccr-2020/>, <https://onco.cc/key-papers/paper-lengauer-genetic-instability-colorectal-nature-1997/>, <https://onco.cc/key-papers/paper-markowitz-tgfbr2-inactivation-msi-colon-science-1995/>, <https://onco.cc/key-papers/paper-tcga-colorectal-comprehensive-characterization-nature-2012/>, <https://onco.cc/key-papers/paper-seshagiri-rspo-fusions-colon-nature-2012/>, <https://onco.cc/key-papers/paper-giannakis-genomic-correlates-immune-colorectal-cell-rep-2016/>, <https://onco.cc/key-papers/paper-yaeger-metastatic-colorectal-genomic-landscape-cancer-cell-2018/>, <https://onco.cc/key-papers/paper-grasso-immune-evasion-colorectal-cancer-discov-2018/>, <https://onco.cc/key-papers/paper-herman-mlh1-promoter-hypermethylation-colorectal-pnas-1998/>, <https://onco.cc/key-papers/paper-weisenberger-cimp-braf-mlh1-colorectal-nat-genet-2006/>, <https://onco.cc/key-papers/paper-ligtenberg-epcam-deletion-msh2-silencing-nat-genet-2009/>, <https://onco.cc/key-papers/paper-moreira-lynch-syndrome-identification-jama-2012/>, <https://onco.cc/key-papers/paper-koopman-deficient-mismatch-repair-advanced-colorectal-bjc-2009/>, <https://onco.cc/key-papers/paper-venderbosch-mmr-braf-metastatic-colorectal-pooled-ccr-2014/>, <https://onco.cc/key-papers/paper-palles-germline-pole-pold1-proofreading-nat-genet-2013/>, <https://onco.cc/key-papers/paper-domingo-somatic-pole-proofreading-colorectal-lancet-gastro-2016/>, <https://onco.cc/key-papers/paper-bettington-serrated-pathway-colorectal-histopathology-2013/>, <https://onco.cc/key-papers/paper-crockett-nagtegaal-serrated-neoplasia-gastroenterology-2019/>, <https://onco.cc/key-papers/paper-lee-six-somatic-mutation-normal-colorectal-crypts-nature-2019/>, <https://onco.cc/key-papers/paper-isella-stromal-contribution-colorectal-transcriptome-nat-genet-2015/>, <https://onco.cc/key-papers/paper-calon-stromal-gene-expression-poor-prognosis-colorectal-nat-genet-2015/>, <https://onco.cc/key-papers/paper-tauriello-tgfbeta-immune-evasion-colorectal-nature-2018/>, <https://onco.cc/key-papers/paper-lenz-cms-calgb-swog-80405-jco-2019/>, <https://onco.cc/key-papers/paper-missiaglia-distal-proximal-colon-cancers-ann-oncol-2014/>, <https://onco.cc/key-papers/paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017/>, <https://onco.cc/key-papers/paper-loree-tumour-location-continuum-colorectal-ccr-2018/>, <https://onco.cc/key-papers/paper-karapetis-kras-cetuximab-colorectal-nejm-2008/>, <https://onco.cc/key-papers/paper-jones-non-v600-braf-colorectal-jco-2017/>, <https://onco.cc/key-papers/paper-schirripa-kras-g12c-metastatic-colorectal-clin-colorectal-cancer-2020/>, <https://onco.cc/key-papers/paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012/>, <https://onco.cc/key-papers/paper-diaz-molecular-evolution-egfr-resistance-colorectal-nature-2012/>, <https://onco.cc/key-papers/paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011/>, <https://onco.cc/key-papers/paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015/>, <https://onco.cc/key-papers/paper-richman-her2-amplification-quasar-focus-piccolo-j-pathol-2016/>, <https://onco.cc/key-papers/paper-nakamura-triumph-ctdna-pertuzumab-trastuzumab-her2-colorectal-nat-med-2021/>, <https://onco.cc/key-papers/paper-overman-checkmate-142-nivolumab-dmmr-colorectal-lancet-oncol-2017/>, <https://onco.cc/key-papers/paper-eng-imblaze370-atezolizumab-cobimetinib-colorectal-lancet-oncol-2019/>, <https://onco.cc/key-papers/paper-mlecnik-immunoscore-msi-colorectal-immunity-2016/>, <https://onco.cc/key-papers/paper-pages-immunoscore-international-validation-lancet-2018/>, <https://onco.cc/key-papers/paper-reinert-ctdna-ultradeep-sequencing-colorectal-jama-oncol-2019/>, <https://onco.cc/key-papers/paper-henriksen-ctdna-stage-iii-colorectal-improve-it-ccr-2022/>, <https://onco.cc/key-papers/paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017/>, <https://onco.cc/key-papers/paper-fearon-cell/>, <https://onco.cc/key-papers/paper-cms-guinney-nat-med-2015/>, <https://onco.cc/key-papers/paper-keynote-177-nejm-2020/>, <https://onco.cc/key-papers/paper-niche-2-nejm-2024/>, <https://onco.cc/key-papers/paper-cercek-dostarlimab-rectal-nejm-2022/>, <https://onco.cc/key-papers/paper-kopetz-beacon-encorafenib-braf-colorectal-nejm-2019/>, <https://onco.cc/key-papers/paper-breakwater-nejm-2025/>, <https://onco.cc/key-papers/paper-krystal-1-crc-yaeger-nejm-2023/>, <https://onco.cc/key-papers/paper-codebreak-300-nejm-2023/>, <https://onco.cc/key-papers/paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023/>, <https://onco.cc/key-papers/paper-destiny-crc02-lancet-oncol-2024/>, <https://onco.cc/key-papers/paper-paradigm-jama-2023/>, <https://onco.cc/key-papers/paper-dynamic-nejm-2022/>, <https://onco.cc/key-papers/paper-galaxy-signatera-nat-med-2023/>, <https://onco.cc/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/>, <https://onco.cc/key-papers/paper-le-mmr-deficiency-science-2017/>, <https://onco.cc/key-papers/paper-galon-immune-contexture-colorectal-science-2006/> ;
  onco:journals <https://onco.cc/journals/clinical-colorectal-cancer/>, <https://onco.cc/journals/journal-of-gastrointestinal-cancer/> ;
  onco:pipeline <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/autogene-cevumeran/>, <https://onco.cc/drugs/signatera/>, <https://onco.cc/drugs/pf-08634404/>, <https://onco.cc/drugs/shr-8068/>, <https://onco.cc/drugs/pm8002/>, <https://onco.cc/drugs/telisotuzumab-adizutecan/>, <https://onco.cc/drugs/oleclumab/>, <https://onco.cc/drugs/calderasib/>, <https://onco.cc/drugs/ak117/>, <https://onco.cc/drugs/yl202/>, <https://onco.cc/drugs/jdq443/>, <https://onco.cc/drugs/ql1706/>, <https://onco.cc/drugs/gotistobart/>, <https://onco.cc/drugs/sitneprotafib/>, <https://onco.cc/drugs/grt-c901/>, <https://onco.cc/drugs/grt-r902/>, <https://onco.cc/drugs/hr070803/>, <https://onco.cc/drugs/sgm-101/>, <https://onco.cc/drugs/precemtabart-tocentecan/>, <https://onco.cc/drugs/inca33890/>, <https://onco.cc/drugs/ibi363/>, <https://onco.cc/drugs/vs-7375/>, <https://onco.cc/drugs/mcla-129/>, <https://onco.cc/drugs/ak119/>, <https://onco.cc/drugs/xnw27011/>, <https://onco.cc/drugs/tqb2922/>, <https://onco.cc/drugs/abt-301/>, <https://onco.cc/drugs/botensilimab/>, <https://onco.cc/drugs/jk08/>, <https://onco.cc/drugs/hdm2017/>, <https://onco.cc/drugs/jyp0015/>, <https://onco.cc/drugs/eik1005/>, <https://onco.cc/drugs/onvansertib/>, <https://onco.cc/drugs/ct3001/>, <https://onco.cc/drugs/sotevtamab/>, <https://onco.cc/drugs/jmt203/>, <https://onco.cc/drugs/tst003/>, <https://onco.cc/drugs/vb15010/>, <https://onco.cc/trials/azur-1/>, <https://onco.cc/trials/mountaineer/>, <https://onco.cc/trials/circulate-japan/>, <https://onco.cc/drugs/zoldonrasib/>, <https://onco.cc/trials/checkmate-8hw/>, <https://onco.cc/ideas/idea-ctdna-guided-adjuvant-crc/>, <https://onco.cc/ideas/idea-immunotherapy-mss-crc/>, <https://onco.cc/pairings/neoadjuvant-io-dmmr/>, <https://onco.cc/technologies/colorectal-screening/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/divarasib/>, <https://onco.cc/drugs/olomorasib/>, <https://onco.cc/drugs/eli-002-7p/>, <https://onco.cc/drugs/shield/>, <https://onco.cc/ideas/idea-crc-early-onset-cause-hunt/>, <https://onco.cc/ideas/idea-crc-screening-uptake-and-age-extension/>, <https://onco.cc/ideas/idea-crc-ctdna-de-escalation-beyond-stage-ii/>, <https://onco.cc/ideas/idea-crc-organ-preservation-randomised-in-pmmr-rectal/>, <https://onco.cc/ideas/idea-crc-mss-immunotherapy-by-biomarker-not-by-line/>, <https://onco.cc/ideas/idea-crc-peritoneal-disease-found-early-and-treated-in-networks/>, <https://onco.cc/ideas/idea-crc-exercise-as-a-funded-treatment/>, <https://onco.cc/ideas/idea-crc-uk-colonoscopy-capacity-and-fit-threshold/>, <https://onco.cc/ideas/idea-crc-uk-young-patient-referral-and-diagnostic-interval/>, <https://onco.cc/trials/mountaineer-03/>, <https://onco.cc/trials/nct05855200/>, <https://onco.cc/trials/nct06252649/>, <https://onco.cc/trials/nct04793958/>, <https://onco.cc/trials/circulate-us/>, <https://onco.cc/trials/tracc/>, <https://onco.cc/trials/nct05608044/>, <https://onco.cc/trials/chronos/>, <https://onco.cc/trials/cave/> ;
  onco:standardOfCare <https://onco.cc/terms/colectomy/>, <https://onco.cc/terms/total-mesorectal-excision/>, <https://onco.cc/terms/stoma/>, <https://onco.cc/technologies/prehabilitation/>, <https://onco.cc/technologies/eras-perioperative-nutrition/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/trials/dynamic/>, <https://onco.cc/terms/total-neoadjuvant-therapy/>, <https://onco.cc/terms/organ-preservation/>, <https://onco.cc/terms/total-mesorectal-excision/>, <https://onco.cc/trials/rapido/>, <https://onco.cc/trials/prodige-23/>, <https://onco.cc/trials/opra/>, <https://onco.cc/trials/prospect/>, <https://onco.cc/trials/cao-aro-aio-94/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/folfiri/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/panitumumab/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/trials/paradigm/>, <https://onco.cc/trials/crystal-fire3/>, <https://onco.cc/trials/breakwater/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/mss-pmmr/>, <https://onco.cc/terms/sidedness/>, <https://onco.cc/terms/hepatectomy/>, <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/technologies/microwave-rf-ablation/>, <https://onco.cc/terms/liver-directed-therapy/>, <https://onco.cc/technologies/hipec/>, <https://onco.cc/trials/sabr-comet/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/trials/keynote-177/>, <https://onco.cc/trials/checkmate-8hw/>, <https://onco.cc/trials/niche-2/>, <https://onco.cc/trials/azur-1/>, <https://onco.cc/terms/msi/>, <https://onco.cc/technologies/msi-mmr-testing/>, <https://onco.cc/drugs/trifluridine-tipiracil/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/fruquintinib/>, <https://onco.cc/drugs/regorafenib/>, <https://onco.cc/trials/sunlight/>, <https://onco.cc/trials/fresco-2/>, <https://onco.cc/terms/lynch-syndrome/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/msi-mmr-testing/>, <https://onco.cc/terms/mlh1-promoter-methylation/>, <https://onco.cc/terms/colonoscopy/>, <https://onco.cc/drugs/aspirin/>, <https://onco.cc/trials/focus4/>, <https://onco.cc/trials/azur-1/>, <https://onco.cc/trials/dynamic/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/terms/curative-intent/>, <https://onco.cc/trials/quasar/>, <https://onco.cc/trials/dynamic/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/terms/msi/>, <https://onco.cc/technologies/cea-surveillance-colorectal/>, <https://onco.cc/trials/scot/>, <https://onco.cc/trials/quasar/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/terms/msi/>, <https://onco.cc/trials/mosaic/>, <https://onco.cc/trials/idea-collaboration/>, <https://onco.cc/trials/scot/>, <https://onco.cc/trials/tosca/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/trials/n0147/>, <https://onco.cc/trials/petacc-8/>, <https://onco.cc/trials/atomic/>, <https://onco.cc/trials/niche-2/>, <https://onco.cc/trials/nct05855200/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/terms/msi/>, <https://onco.cc/trials/foxtrot/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/trials/niche-2/>, <https://onco.cc/trials/dutch-tme-trial/>, <https://onco.cc/trials/cao-aro-aio-94/>, <https://onco.cc/trials/rapido/>, <https://onco.cc/trials/prodige-23/>, <https://onco.cc/trials/stellar-rectal/>, <https://onco.cc/trials/stockholm-iii/>, <https://onco.cc/trials/prospect/>, <https://onco.cc/terms/total-neoadjuvant-therapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/trials/opra/>, <https://onco.cc/trials/cao-aro-aio-12/>, <https://onco.cc/trials/iwwd/>, <https://onco.cc/trials/azur-1/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/terms/clinical-complete-response/>, <https://onco.cc/terms/organ-preservation/>, <https://onco.cc/trials/keynote-177/>, <https://onco.cc/trials/checkmate-8hw/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/colorectal-uk-drug-access/>, <https://onco.cc/trials/paradigm/>, <https://onco.cc/trials/crystal-fire3/>, <https://onco.cc/trials/calgb-80405/>, <https://onco.cc/trials/prime/>, <https://onco.cc/trials/opus/>, <https://onco.cc/drugs/panitumumab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/folfiri/>, <https://onco.cc/terms/sidedness/>, <https://onco.cc/pairings/anti-egfr-left-sided/>, <https://onco.cc/trials/tribe/>, <https://onco.cc/trials/tribe2/>, <https://onco.cc/trials/cairo3/>, <https://onco.cc/trials/avf2107g/>, <https://onco.cc/drugs/folfoxiri/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/terms/sidedness/>, <https://onco.cc/trials/breakwater/>, <https://onco.cc/trials/beacon-crc/>, <https://onco.cc/trials/swog-s1406/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/trials/codebreak-300/>, <https://onco.cc/trials/nct04793958/>, <https://onco.cc/trials/nct06252649/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/panitumumab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/pairings/kras-plus-egfr-crc/>, <https://onco.cc/trials/mountaineer/>, <https://onco.cc/trials/mountaineer-03/>, <https://onco.cc/trials/destiny-crc01/>, <https://onco.cc/trials/destiny-crc02/>, <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/technologies/companion-diagnostic/>, <https://onco.cc/trials/sunlight/>, <https://onco.cc/trials/fresco-2/>, <https://onco.cc/trials/correct/>, <https://onco.cc/trials/concur/>, <https://onco.cc/trials/recourse/>, <https://onco.cc/trials/fresco/>, <https://onco.cc/trials/velour/>, <https://onco.cc/trials/raise/>, <https://onco.cc/drugs/trifluridine-tipiracil/>, <https://onco.cc/drugs/fruquintinib/>, <https://onco.cc/drugs/regorafenib/>, <https://onco.cc/drugs/ziv-aflibercept/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/trials/chronos/>, <https://onco.cc/trials/cave/>, <https://onco.cc/drugs/panitumumab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/trials/imblaze370/>, <https://onco.cc/trials/nct05608044/>, <https://onco.cc/drugs/botensilimab/>, <https://onco.cc/drugs/balstilimab/>, <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/msi/>, <https://onco.cc/ideas/idea-immunotherapy-mss-crc/>, <https://onco.cc/trials/eortc-40983/>, <https://onco.cc/trials/clocc/>, <https://onco.cc/trials/cairo5/>, <https://onco.cc/trials/new-epoc/>, <https://onco.cc/terms/hepatectomy/>, <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/terms/oligometastatic/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/trials/prodige-7/>, <https://onco.cc/trials/colopec/>, <https://onco.cc/trials/prophylochip/>, <https://onco.cc/technologies/hipec/>, <https://onco.cc/terms/debulking/>, <https://onco.cc/terms/colorectal-failed-programmes/>, <https://onco.cc/trials/dynamic/>, <https://onco.cc/trials/dynamic-iii/>, <https://onco.cc/trials/altair/>, <https://onco.cc/trials/circulate-japan/>, <https://onco.cc/trials/circulate-us/>, <https://onco.cc/trials/bespoke-crc/>, <https://onco.cc/trials/tracc/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/colorectal-failed-programmes/>, <https://onco.cc/trials/n0147/>, <https://onco.cc/trials/petacc-8/>, <https://onco.cc/trials/new-epoc/>, <https://onco.cc/trials/prodige-7/>, <https://onco.cc/trials/colopec/>, <https://onco.cc/trials/prophylochip/>, <https://onco.cc/trials/imblaze370/>, <https://onco.cc/trials/altair/>, <https://onco.cc/terms/colorectal-uk-drug-access/>, <https://onco.cc/terms/cancer-drugs-fund/>, <https://onco.cc/terms/colorectal-palliation-obstruction-pain/>, <https://onco.cc/terms/stoma/>, <https://onco.cc/technologies/endoscopic-resection/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/terms/colorectal-palliation-obstruction-pain/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/transfusion-support/>, <https://onco.cc/terms/fit-test/>, <https://onco.cc/terms/colonoscopy/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/msi-mmr-testing/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/terms/circumferential-resection-margin/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/cea-surveillance-colorectal/>, <https://onco.cc/terms/obstructing-colorectal-cancer/>, <https://onco.cc/terms/endoscopy/>, <https://onco.cc/terms/colectomy/>, <https://onco.cc/terms/colonoscopy-surveillance-intervals/>, <https://onco.cc/terms/colorectal-polyp-types/>, <https://onco.cc/technologies/aspirin-cancer-prevention/>, <https://onco.cc/terms/lynch-syndrome/>, <https://onco.cc/technologies/colorectal-screening/>, <https://onco.cc/technologies/exercise-oncology/>, <https://onco.cc/technologies/cea-surveillance-colorectal/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/terms/colonoscopy/>, <https://onco.cc/terms/colonoscopy-surveillance-intervals/>, <https://onco.cc/terms/fit-test/>, <https://onco.cc/terms/bowel-cancer-screening-uk/>, <https://onco.cc/terms/emergency-presentation/> .